Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A.

Cancer Discovery
Matthew J MartinRichard Marais

Abstract

The antidiabetic drug metformin has antitumor activity in a variety of cancers because it blocks cell growth by inhibiting TORC1. Here, we show that melanoma cells that are driven by oncogenic BRAF are resistant to the growth-inhibitory effects of metformin because RSK sustains TORC1 activity even when AMP-activated protein kinase (AMPK) is activated. We further show that AMPK targets the dual-specificity protein phosphatase DUSP6 for degradation and this increases ERK activity, which then upregulates the VEGF-A protein. Critically, this drives angiogenesis and accelerates the growth of BRAF-driven tumors in mice. Unexpectedly, however, when VEGF signaling is inhibited, instead of accelerating tumor growth, metformin inhibits tumor growth. Thus, we show that BRAF-driven melanoma cells are resistant to the antigrowth effects of AMPK and that AMPK mediates cell-autonomous and cell-nonautonomous effects that accelerate the growth of these cells in vivo. Metformin inhibits the growth of most tumor cells, but BRAF-mutant melanoma cells are resistant to metformin in vitro, and metformin accelerates their growth in vivo. Unexpectedly, VEGF inhibitors and metformin synergize to suppress the growth of BRAF-mutant tumors, revealing a com...Continue Reading

References

Dec 22, 1999·Biochemical and Biophysical Research Communications·D E RichardJ Pouysségur
Feb 19, 2000·Current Biology : CB·A ShimamuraJ Blenis
Oct 17, 2001·The Journal of Clinical Investigation·G ZhouD E Moller
Jun 28, 2003·FEBS Letters·D Grahame HardieEmma R Hudson
Apr 26, 2005·BMJ : British Medical Journal·Josie M M EvansAndrew D Morris
Oct 3, 2006·Biochimica Et Biophysica Acta·Pekka KatajistoTomi P Mäkelä
Oct 26, 2006·Cancer Research·Mahvash ZakikhaniMichael Pollak
Feb 23, 2007·Nature·Vanessa Gray-SchopferRichard Marais
May 27, 2008·Cancer Chemotherapy and Pharmacology·Marc Lacroix
Oct 16, 2008·The Journal of Biological Chemistry·Fiona C DenisonAngela Woods
Mar 3, 2009·Proceedings of the National Academy of Sciences of the United States of America·Christine A PratilasNeal Rosen
Mar 24, 2009·Nature Medicine·Andrew R ReynoldsKairbaan M Hodivala-Dilke
Jun 25, 2009·Cancer Research·Ann F Chambers
Aug 18, 2009·Pigment Cell & Melanoma Research·Leisl M PackerRichard Marais
Sep 26, 2009·Biochimica Et Biophysica Acta·S Fogarty, D G Hardie
Jul 6, 2010·Biochemical and Biophysical Research Communications·Jennifer Woodard, Leonidas C Platanias
Sep 3, 2010·Cancer Prevention Research·Regan M MemmottPhillip A Dennis
Sep 8, 2010·The New England Journal of Medicine·Keith T FlahertyPaul B Chapman
Oct 16, 2010·Cancer Prevention Research·Andrea DecensiSara Gandini
Jun 7, 2011·The New England Journal of Medicine·Paul B ChapmanUNKNOWN BRIM-3 Study Group

❮ Previous
Next ❯

Citations

Jun 19, 2013·Trends in Endocrinology and Metabolism : TEM·Brendan J QuinnPhillip A Dennis
Oct 2, 2013·Nature Reviews. Clinical Oncology·Naomi Gronich, Gad Rennert
Sep 4, 2013·The Journal of Clinical Investigation·Michael Pollak
Sep 1, 2012·CNS Oncology·Eric C Woolf, Adrienne C Scheck
Oct 23, 2013·Proceedings of the National Academy of Sciences of the United States of America·Ping YuanBin Zheng
May 16, 2014·Rejuvenation Research·Andrew R Mendelsohn, James W Larrick
Jan 15, 2014·Carcinogenesis·Katiuscia DallaglioAdriana Albini
Oct 30, 2015·Expert Opinion on Pharmacotherapy·Andrea Casadei GardiniGiovanni Luca Frassineti
Dec 20, 2012·Expert Review of Anticancer Therapy·Emma Dean, Paul Lorigan
Aug 14, 2013·Expert Opinion on Investigational Drugs·Floriana MorgilloFortunato Ciardiello
Sep 22, 2015·Autophagy·Harun-Or RashidHan-Jung Chae
Jan 21, 2014·The Journal of Investigative Dermatology·Madhuri BhandaruAnand Rotte
Apr 8, 2015·Experimental Hematology·Ichiro KawashimaKeita Kirito
Jul 20, 2012·Cell Cycle·Javier A MenendezAlejandro Vazquez-Martin
Apr 29, 2016·Thyroid : Official Journal of the American Thyroid Association·Juliana M CazarinDenise P Carvalho
Mar 22, 2016·Indian Journal of Pharmacology·Aditya Kumar Bubna
Jan 22, 2015·Cancer Biology & Therapy·Stefano IndraccoloMaria Ornella Nicoletto
May 9, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew Martin, Richard Marais
May 28, 2014·Pigment Cell & Melanoma Research·Michael CerezoStéphane Rocchi
Oct 31, 2015·Pigment Cell & Melanoma Research·Daniela Senft, Ze'ev A Ronai
Aug 2, 2014·International Journal of Cancer. Journal International Du Cancer·Floris H GroenendijkRené Bernards
Feb 18, 2017·International Journal of Molecular Sciences·Annelies GonnissenKarin Haustermans
Jun 2, 2018·Medicinal Research Reviews·Hui HuaYangfu Jiang
Jun 5, 2012·Nature·Robert U Svensson, Reuben J Shaw
Jun 4, 2019·International Journal of Molecular Sciences·Hsueh-Fen ChenTse-Hua Tan
Apr 27, 2013·Expert Review of Anticancer Therapy·Heather M Shaw, Paul D Nathan
Mar 13, 2019·Oncotarget·Karoline KollmannChristoph Hoeller
Oct 27, 2016·Oncotarget·Young Kwang ChaeFrancis Giles
Sep 13, 2014·International Journal of Oncology·Katarzyna BrodowskaDemetrios G Vavvas
Feb 17, 2017·Biochemical Society Transactions·Coralie DorardManuela Baccarini

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.